MX2016005940A - Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia. - Google Patents

Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia.

Info

Publication number
MX2016005940A
MX2016005940A MX2016005940A MX2016005940A MX2016005940A MX 2016005940 A MX2016005940 A MX 2016005940A MX 2016005940 A MX2016005940 A MX 2016005940A MX 2016005940 A MX2016005940 A MX 2016005940A MX 2016005940 A MX2016005940 A MX 2016005940A
Authority
MX
Mexico
Prior art keywords
treatment
hyperkalemia
compositions
zirconium silicate
microporous zirconium
Prior art date
Application number
MX2016005940A
Other languages
English (en)
Inventor
Jeffrey Keyser Donald
F Guillem Alvaro
Original Assignee
Zs Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zs Pharma Inc filed Critical Zs Pharma Inc
Publication of MX2016005940A publication Critical patent/MX2016005940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevas composiciones de silicato de zirconio microporoso que están formuladas para eliminar las toxinas, por ejemplo, iones potasio, del tracto gastrointestinal a una velocidad elevada sin causar efectos secundarios indeseables. La composición preferida tiene al menos 95% de ZS-9. Estas composiciones son particularmente útiles en el tratamiento terapéutico de la hiperpotasemia. Estas composiciones también son útiles en el tratamiento de la enfermedad renal crónica, enfermedad vascular coronaria, diabetes mellitus y el rechazo de trasplantes.
MX2016005940A 2013-11-08 2014-11-07 Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia. MX2016005940A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361901886P 2013-11-08 2013-11-08
US201361914354P 2013-12-10 2013-12-10
US201461930328P 2014-01-22 2014-01-22
US201461930336P 2014-01-22 2014-01-22
US201462005484P 2014-05-30 2014-05-30
US201462015215P 2014-06-20 2014-06-20
US201462053732P 2014-09-22 2014-09-22
PCT/US2014/064548 WO2015070019A1 (en) 2013-11-08 2014-11-07 Microporous zirconium silicate for the treatment of hyperkalemia

Publications (1)

Publication Number Publication Date
MX2016005940A true MX2016005940A (es) 2016-08-17

Family

ID=53042126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005940A MX2016005940A (es) 2013-11-08 2014-11-07 Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia.

Country Status (14)

Country Link
US (2) US20150290242A1 (es)
EP (2) EP3065710A4 (es)
JP (1) JP2016535754A (es)
KR (1) KR102332954B1 (es)
CN (1) CN106170283B (es)
AU (1) AU2014346576B2 (es)
CA (1) CA2929978C (es)
CL (1) CL2016001095A1 (es)
IL (1) IL245526B (es)
MX (1) MX2016005940A (es)
PH (1) PH12016500864A1 (es)
TW (1) TW201607543A (es)
WO (1) WO2015070019A1 (es)
ZA (1) ZA201603171B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160038538A1 (en) * 2013-11-08 2016-02-11 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
US10668098B2 (en) * 2017-07-07 2020-06-02 Hemocleanse Technology Llc Oral sorbent for removing toxins of kidney failure combining anion and cation exchangers
AU2018360868A1 (en) * 2017-11-03 2020-04-30 Tricida, Inc. Method of treating acid-base disorders
WO2019092179A1 (en) * 2017-11-10 2019-05-16 Sandoz Ag Pharmaceutical compositions comprising zs-9
MX2021011044A (es) * 2019-03-13 2021-10-13 Astrazeneca Ab Agentes de union a potasio para su uso en pacientes de hemodialisis.
EP4255488A1 (en) * 2020-12-01 2023-10-11 Nanobiotix Porous, high-z and carbon-free particles as radioenhancers
CN117342570A (zh) * 2023-09-04 2024-01-05 杭州国瑞生物科技有限公司 一种环硅酸锆钠的a晶型及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3329480A (en) * 1963-10-18 1967-07-04 Union Oil Co Crystalline zircono-silicate zeolites
US4581141A (en) * 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
ATE167459T1 (de) * 1990-05-28 1998-07-15 Engelhard Corp Grossporige molekularsiebe mit mindenstens einer octahedrischen position und tetrahedrischen positionen von mindestens einer type
US5338527A (en) * 1992-08-20 1994-08-16 Uop Zirconium silicate composition, method of preparation and uses thereof
US5891417A (en) * 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US5888472A (en) * 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
EP1038580B1 (en) * 1999-03-26 2005-05-25 Uop Llc Ammonium ion adsorption process using zirconium silicate and zirconium germanate molecular sieves
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US20040105895A1 (en) * 2001-02-06 2004-06-03 Ash Stephen R Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US6814871B1 (en) 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
US7556799B2 (en) * 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP3246287A1 (en) * 2011-02-11 2017-11-22 ZS Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
CN104968336A (zh) * 2012-07-11 2015-10-07 Zs制药公司 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物
JP6423795B2 (ja) * 2012-10-22 2018-11-14 ズィーエス・ファーマ，インコーポレーテッド 高カリウム血症を治療するための微多孔性ケイ酸ジルコニウム

Also Published As

Publication number Publication date
US20150374748A1 (en) 2015-12-31
CA2929978A1 (en) 2015-05-14
CA2929978C (en) 2021-11-30
WO2015070019A1 (en) 2015-05-14
JP2016535754A (ja) 2016-11-17
CN106170283B (zh) 2019-08-20
TW201607543A (zh) 2016-03-01
EP3065710A4 (en) 2017-05-17
EP3065710A1 (en) 2016-09-14
IL245526A0 (en) 2016-06-30
AU2014346576A1 (en) 2016-06-09
ZA201603171B (en) 2020-11-25
KR102332954B1 (ko) 2021-11-29
PH12016500864A1 (en) 2016-07-18
AU2014346576B2 (en) 2020-03-26
EP4378577A2 (en) 2024-06-05
CL2016001095A1 (es) 2016-11-11
US20150290242A1 (en) 2015-10-15
IL245526B (en) 2020-01-30
KR20160073424A (ko) 2016-06-24
CN106170283A (zh) 2016-11-30

Similar Documents

Publication Publication Date Title
PH12016500864A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
SA518391624B1 (ar) Ror- منظمات جاما
MX2017013556A (es) Compuestos novedosos.
MX2020010674A (es) Agonistas del receptor muscarinico.
MA40893A (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
WO2015028969A3 (en) Transduction buffer
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
MX354955B (es) Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).
NZ746950A (en) Heterocyclic gpr119 agonist compounds
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
PH12018500578A1 (en) Methods of treating inflammatory diseases
PH12016500861A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
WO2014011876A3 (en) Zirconium silicate for treatment of hyperkalemia
WO2014151456A3 (en) Treatment of inflammatory diseases
PH12017501133A1 (en) Pyrazolopyridinamines
PH12015501360A1 (en) Bmp-6 antibodies
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MY189930A (en) Glyt1 inhibitors for use in the treatment of hematological disorders
WO2013190497A3 (en) Compositions and methods for treatment of inflammatory diseases of the lung
FR2978012B1 (fr) Agent pour le traitement des bois de vigne
WO2016122943A3 (en) Compounds, compositions, and methods for using hla-f
EA201301083A1 (ru) Комплексные соединения железа(iii) для лечения и профилактики симптомов железодефицита и железодефицитной анемии